Medtronic MDT · NYSE
$91.87 +3.83% (+$3.39)
Summary
83 / 100 · Bulios Score
What speaks for it
- It has raised its dividend 25 years in a row.
- Out of every 100 USD of revenue, 14 USD is left as net profit.
- It has no debt and holds $1.79B in cash.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 7.3% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensivePrice against the Bulios Fair Price
P/E against its own last 5 years
P/E against the industry (Medical - Devices)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 21.7 USD for 1 USD of yearly profit. Over the last five years it was 27.0 USD on average.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.0% a year over 5 years. Over the last 3 years it grew by 2.6% a year. For the next fiscal year analysts expect revenue to fall by 0.6%. Earnings per share fell by 7.3% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 33 USD
- Research and development 7.8 USD
- Sales and administration 41 USD
- Taxes and other 4.1 USD
- Net profit 14 USD
Net profit, industry median (Medical - Devices) 12 USD
Out of every 100 USD of revenue, 14 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 3.23%
- Paid out of profit
- 70%
- Raised in a row
- 25 years
You receive $2.86 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 31
- Hold 20
- Sell 0
Today's price within the analysts' price targets
The average target of $98 is 6.7% above today's price. 61% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- Cardiac and Vascular Group 39%
- Neuroscience Group 28%
- Medical Surgical 24%
- Diabetes Group 8.6%
By region
- UNITED STATES 80%
- Total Other Countries, Excluding United States and Ireland 20%
- IRELAND 0.2%
Cardiac and Vascular Group brings in 39% of revenue. Diabetes Group grew fastest, by 7.4% a year.
Segments in detail